Analyzing Jade Biosciences (NASDAQ:JBIO) and Ensysce Biosciences (NASDAQ:ENSC)

Jade Biosciences (NASDAQ:JBIO) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.

Insider and Institutional Ownership

5.6% of Ensysce Biosciences shares are owned by institutional investors. 24.9% of Jade Biosciences shares are owned by insiders. Comparatively, 2.8% of Ensysce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Jade Biosciences has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Ensysce Biosciences has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500.

Valuation & Earnings

This table compares Jade Biosciences and Ensysce Biosciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41 million	($4.61)	-3.88
Ensysce Biosciences	$5.07 million	0.85	-$10.18 million	($4.22)	-0.11

Ensysce Biosciences has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for Jade Biosciences and Ensysce Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1	1	5	2	2.89
Ensysce Biosciences	1	0	0	0	1.00

Jade Biosciences presently has a consensus target price of $29.50, suggesting a potential upside of 64.90%. Given Jade Biosciences’ stronger consensus rating and higher probable upside, equities analysts clearly believe Jade Biosciences is more favorable than Ensysce Biosciences.

Profitability

This table compares Jade Biosciences and Ensysce Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-46.55%	-42.99%
Ensysce Biosciences	-200.87%	-426.62%	-195.53%

Summary

Jade Biosciences beats Ensysce Biosciences on 8 of the 14 factors compared between the two stocks.

About Jade Biosciences

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

About Ensysce Biosciences

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.